NR1H4 and Hypercholesterolemia: Intestinal FXR is activated in high-fat-fed mice and the use of intestinal FXR inhibitors could reduce ceramide production and control hypercholesterolemia, leading to new directions in the treatment of atherosclerosis (Wu et al., 2021).